L-Fucose

L-Fucose

SCHEMBL525352

C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O.C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
L-Fucose SCHEMBL16703726 1.00
L-Fucose SCHEMBL14830475 1.00
L-Fucose SCHEMBL5072536 1.00
L-Fucose SCHEMBL25051 1.00
L-Fucose SCHEMBL3462756 1.00
L-Fucose SCHEMBL466429 1.00
L-Fucose SCHEMBL2597764 1.00
L-Fucose SCHEMBL1746724 1.00
L-Fucose SCHEMBL11347428 1.00
L-Fucose SCHEMBL1458729 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3371206-B1 METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEIN HOFFMANN LA ROCHE (CH) 2021-04-14 EP claimed
EP-1664352-B1 SEPARATION OF SUGARS DUPONT NUTRITION BIOSCI APS (DK) 2015-12-30 EP claimed
EP-2978857-A2 RECOMBINANT PHAGE AND BACTERIAL DETECTION METHODS Sample Technologies, Inc. (US) 2016-02-03 EP disclosed
CN-105087556-A Primer, kit and method for detecting poppy shell components based on LAMP technology CHEN DINGHU 2015-11-25 CN disclosed
WO-2015172082-A1 CODON-OPTIMIZED RECOMBINANT PHAGE AND METHODS OF USING SAME SAMPLE6 TECHNOLOGIES, INC. (US) 2015-11-12 WO disclosed
WO-2014160818-A2 RECOMBINANT PHAGE AND BACTERIAL DETECTION METHODS SAMPLE TECHNOLOGIES, INC. (US) 2014-10-02 WO disclosed
EP-2760477-A1 DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS Alnylam Pharmaceuticals, Inc. (US) 2014-08-06 EP disclosed
CN-103319282-B Disease and insect resistant fertilizer produced by traditional Chinese medicines and preparation technology thereof WEI WENLI 2014-08-06 CN disclosed
WO-2013049328-A9 DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-12-27 WO disclosed
EP-2663548-A1 PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY Alnylam Pharmaceuticals, Inc. (US) 2013-11-20 EP disclosed
CN-103319282-A Disease and insect resistant fertilizer produced by traditional Chinese medicines and preparation technology thereof WEI WENLI 2013-09-25 CN disclosed
WO-2011094580-A2 CHELATED COPPER FOR USE IN THE PREPARATION OF CONJUGATED OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. (US) 2011-08-04 WO disclosed
WO-2011075656-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-06-23 WO disclosed
WO-2009142822-A9 2-F MODIFIED RNA INTERFERENCE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-01-14 WO disclosed
WO-2010006237-A2 PHOSPHOROTHIOATE OLIGONUCLEOTIDES NON-NUCLEOSIDIC PHOSPHOROTHIOTES AS DELIVERY AGENTS FOR IRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-01-14 WO disclosed
WO-2009142822-A2 2-F MODIFIED RNA INTERFERENCE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
EP-1625138-A2 PROTECTED MONOMERS Alnylam Pharmaceuticals Inc. (US) 2006-02-15 EP disclosed
EP-1615611-A2 iRNA CONJUGATES Alnylam Pharmaceuticals Inc. (US) 2006-01-18 EP disclosed
WO-2004094345-A2 PROTECTED MONOMERS ALNYLAM PHARMACEUTICALS INC. (US) 2004-11-04 WO disclosed
WO-2004091515-A2 iRNA CONJUGATES ALNYLAM PHARMACEUTICALS, INC. (US) 2004-10-28 WO disclosed